🔍

DRREDDY - Dr Reddy's Labs

📊 NSE: DRREDDY 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 21:40

📢 Recent Corporate Announcements

Dr. Reddy's Partner Immutep Discontinues Phase III Lung Cancer Trial for Eftilagimod Alfa

🔴 NEGATIVE ⭐ 6/10

OTHER 📅 13 Mar 2026, 06:40 PM

Dr. Reddy's Laboratories has announced that the Phase III TACTI-004 trial for Eftilagimod Alfa (efti) will be discontinued following a planned interim futility analysis. The study was evaluating the drug for first-line non-small cell lung cancer, a key indication in Dr. Reddy's licensing agreement with Immutep. While Dr. Reddy's SA holds exclusive rights for the drug in regions excluding North America, Europe, Japan, and Greater China, the company has only made an upfront payment to date. This development represents a setback for the company's oncology pipeline in its licensed territories.

Independent Data Monitoring Committee (IDMC) recommended halting the TACTI-004 Phase III study due to futility.
The trial focused on Eftilagimod Alfa for patients with first-line non-small cell lung cancer.
Dr. Reddy's SA holds licensing rights for all countries outside North America, Europe, Japan, and Greater China.
Financial exposure is currently limited as only the initial upfront payment has been made to Immutep.
Immutep is conducting a comprehensive review to determine the next steps for the Eftilagimod Alfa program.

💡 Investors should note this R&D setback which may lead to a minor valuation adjustment for the specialty pipeline. Monitor for any potential write-offs of the upfront payment in upcoming quarterly results.

Dr. Reddy's Allots 10,275 Equity Shares Under ESOP Schemes

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Mar 2026, 12:27 PM

Dr. Reddy's Laboratories has allotted 10,275 equity shares of Re. 1 each to eligible employees on March 12, 2026. These shares were issued following the exercise of stock options under the company's 2002 and 2007 ESOP and ADR schemes. The total paid-up share capital of the company has increased to 83,46,53,295 equity shares. This is a routine administrative action and represents a negligible dilution of the existing share capital.

Allotment of 10,275 equity shares of face value Re. 1 each on March 12, 2026
Exercise price for the allotted shares was Re. 1 per share with nil premium
Total paid-up share capital increased to Rs. 83,46,53,295 post-allotment
Shares issued under the 2002 Employees Stock Options Scheme and 2007 ADR Stock Options Scheme

💡 This is a routine corporate update with no material impact on the company's valuation. Investors should maintain their focus on the company's core pharmaceutical operations and upcoming earnings reports.

Dr. Reddy's Wins Court Approval to Export Semaglutide to Non-Patent Markets

🟢 POSITIVE ⭐ 7/10

LEGAL 📅 10 Mar 2026, 11:52 PM

Dr. Reddy's Laboratories has clarified that the Delhi High Court has ruled in its favor regarding the manufacture and export of Semaglutide. The Division Bench upheld a previous order from March 09, 2026, which allows the company to produce the drug in India for export to countries where Novo Nordisk does not hold patent registrations. This decision follows a legal challenge by Novo Nordisk, which sought an interim injunction against Dr. Reddy's. While the matter remains sub-judice, this ruling provides a significant pathway for Dr. Reddy's to enter the high-growth GLP-1 market internationally.

Delhi High Court Division Bench upheld the March 09, 2026, order allowing Semaglutide production.
Permission granted to export Semaglutide to international markets where Novo Nordisk lacks patent protection.
Court refused to grant an interim injunction requested by Danish pharmaceutical firm Novo Nordisk.
The ruling pertains to Semaglutide-containing products, a key category in diabetes and weight management.
Dr. Reddy's clarified that while the matter is sub-judice, the current ruling supports their manufacturing plans.

💡 Investors should monitor Dr. Reddy's progress in scaling Semaglutide exports to non-patent jurisdictions as it represents a major growth opportunity. The stock may see positive sentiment following this legal clearance for a high-demand product.

Dr. Reddy's Announces Senior Management Reshuffle; M V Ramana Named CEO of Global Generics

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 10 Mar 2026, 07:59 PM

Dr. Reddy's Laboratories has announced a significant restructuring of its senior leadership team effective April 1, 2026. Mr. M S Madhu Sundar, who has 28 years of industrial experience, has been elevated to Global Head of Quality and Pharmacovigilance. Key executive roles have been redefined, including M V Ramana as CEO of Global Generics and Sanjay Sharma as Chief Operating Officer. This reshuffle appears to be a strategic move to streamline global manufacturing, quality, and product development operations.

Mr. M S Madhu Sundar elevated to Global Head of Quality and PV, leveraging 28 years of industry expertise.
Mr. M V Ramana appointed as CEO of Global Generics, a core business segment for the company.
Mr. Sanjay Sharma designated as Chief Operating Officer (COO) effective April 1, 2026.
New leadership appointments made for Integrated Product Development (IPDO) and Consumer Health Organization.

💡 Investors should monitor the transition of these leaders into their new roles, particularly focusing on the execution of the Global Generics strategy. No immediate portfolio changes are recommended as these are internal elevations and planned role transitions.

Dr. Reddy's Cleared by US DOJ in FCPA Investigation; No Enforcement Action Recommended

🟢 POSITIVE ⭐ 8/10

LEGAL 📅 06 Mar 2026, 05:15 PM

Dr. Reddy's Laboratories has received a formal closure letter from the US Department of Justice (DOJ) regarding its investigation into potential Foreign Corrupt Practices Act (FCPA) violations. The inquiry, which began in November 2020, focused on allegations of improper payments to healthcare professionals in Ukraine and other jurisdictions. This follows a similar clearance from the US SEC received on February 23, 2026. The closure of both SEC and DOJ investigations without any recommended enforcement action effectively removes a significant long-term legal overhang for the company.

US DOJ closes inquiry into FCPA violations involving payments in Ukraine and other countries.
No enforcement action recommended by the DOJ Criminal Division, Fraud Section in letter dated March 5, 2026.
Follows a previous clearance from the US SEC received on February 23, 2026.
The investigation had been a disclosed contingency since November 19, 2020.

💡 Investors should view this as a major positive development that eliminates a significant regulatory risk and potential financial liability. The stock may see positive sentiment as this multi-year legal cloud is finally cleared.

Dr. Reddy's Srikakulam Facility Receives VAI Status from USFDA, Inspection Closed

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 05 Mar 2026, 04:04 PM

Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the USFDA for its formulations manufacturing facility (FTO-SEZ PU01) in Srikakulam, Andhra Pradesh. The inspection, which was conducted in December 2025, has been classified as 'Voluntary Action Indicated (VAI)'. This classification indicates that the USFDA has concluded its review and the inspection is now officially closed. This resolution is a positive step as it removes regulatory uncertainty regarding future product approvals from this specific site.

Received Establishment Inspection Report (EIR) from USFDA on March 4, 2026
USFDA classified the inspection outcome as 'Voluntary Action Indicated (VAI)'
Inspection at the Srikakulam (FTO-SEZ PU01) facility is now officially closed
Follows the initial GMP and Pre-Approval Inspection conducted in December 2025

💡 Investors should view this as a positive regulatory clearance that de-risks the company's US supply chain and product pipeline. No immediate action is required, but this strengthens the long-term outlook for the Srikakulam unit.

Dr. Reddy's to Hold Investor Meetings with Ambit Capital and Goldman Sachs in March 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Feb 2026, 12:32 PM

Dr. Reddy's Laboratories has scheduled two upcoming interactions with institutional investors and analysts. The first session is an in-person group meeting organized by Ambit Capital in Hyderabad on March 4, 2026, from 11:00 to 13:30 IST. The second session is a virtual group meeting hosted by Goldman Sachs on March 5, 2026, from 11:15 to 12:15 IST. These meetings are part of the company's regular investor relations engagement to discuss business updates.

In-person group meeting scheduled for March 4, 2026, in Hyderabad with Ambit Capital
Virtual group meeting scheduled for March 5, 2026, with Goldman Sachs
Meetings are conducted under Regulation 30 of SEBI (LODR) Regulations, 2015
Total of two separate institutional investor engagements announced for early March

💡 No immediate action is required as this is a routine disclosure. Investors should look for any post-meeting presentations or transcripts that may be uploaded to the exchange for updates on company strategy.

Dr. Reddy's Acquires Progynova & Cyclo-Progynova for USD 32.15 Million to Enter HRT Segment

🟢 POSITIVE ⭐ 8/10

M&A 📅 18 Feb 2026, 07:45 PM

Dr. Reddy's has entered into a definitive agreement to acquire the trademarks and assets of Progynova and Cyclo-Progynova in India from UK-based Mercury Pharma Group for USD 32.15 million. This acquisition marks the company's strategic entry into the Hormone Replacement Therapy (HRT) segment, significantly strengthening its existing gynecology portfolio. Progynova is currently the #1 brand in the Estradiol represented market in India, with recorded sales of INR 100 crore as of December 2025. The deal allows Dr. Reddy's to leverage its domestic market access to expand the reach of these high-equity specialty brands.

Acquisition of trademarks and related assets for India for a total consideration of USD 32.15 million.
Progynova is the #1 brand in the Estradiol represented pharmaceutical market in India with strong physician equity.
The acquired brand Progynova recorded annual sales of INR 100 crore as per IQVIA MAT December 2025.
Strategic entry into the Hormone Replacement Therapy (HRT) segment to bolster the domestic gynecology portfolio.
Includes Cyclo-Progynova, a combined HRT treatment currently not commercialized in India, providing future growth potential.

💡 Investors should view this as a positive strategic move to diversify the domestic branded portfolio with high-recall specialty brands. Monitor the successful integration and the potential launch of Cyclo-Progynova to drive incremental growth in the gynecology segment.

Dr. Reddy's Allots 12,665 Equity Shares Under Employee Stock Option Schemes

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 17 Feb 2026, 03:58 PM

Dr. Reddy's Laboratories has allotted 12,665 equity shares of Re. 1 each to eligible employees on February 17, 2026. The allotment was carried out following the exercise of options under the company's 2002 and 2007 ESOP and ADR stock option schemes. The exercise prices for these shares varied, with some issued at face value and others at prices up to Rs. 735.80. This is a routine administrative action resulting in a marginal increase in the company's total paid-up share capital.

Allotment of 12,665 equity shares of Re. 1 each on February 17, 2026.
Exercise prices included 5,115 shares at Re. 1, 1,300 at Rs. 735.80, and 6,250 at Rs. 521.40.
Total paid-up share capital increased to 83,46,43,020 equity shares.
The newly allotted shares rank pari passu with existing equity shares of the company.

💡 This is a routine corporate update regarding ESOP allotments with negligible equity dilution. No specific action is required from investors based on this announcement.

Dr. Reddy's to Attend Kotak Institutional Equities Investor Meet on Feb 23, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 03:47 PM

Dr. Reddy's Laboratories has scheduled an in-person group meeting with institutional investors on February 23, 2026. The event is organized by Kotak Institutional Equities and will take place in Mumbai from 09:00 to 17:00 IST. This interaction allows management to engage with key stakeholders regarding the company's business environment. Such meetings are routine and typically do not involve the disclosure of unpublished price-sensitive information.

Management to participate in Kotak Institutional Equities conference on February 23, 2026
The meeting will be an in-person group interaction held in Mumbai
Scheduled timing for the engagement is from 09:00 to 17:00 IST
Compliance filing made under Regulation 30 of SEBI Listing Obligations

💡 No immediate action is required as this is a routine investor engagement. Investors should monitor for any subsequent presentation materials or transcripts for updates on strategic outlook.

Dr. Reddy's Global Head of IPDO Sushrut Kulkarni Resigns Effective May 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 09 Feb 2026, 06:17 PM

Dr. Reddy's Laboratories has announced the resignation of Mr. Sushrut Kulkarni from his position as Global Head of IPDO and Senior Management Personnel. The resignation was disclosed on February 9, 2026, but will only take effect from the close of business hours on May 8, 2026. Mr. Kulkarni is leaving the company to explore opportunities elsewhere. The long notice period of approximately three months suggests a planned transition for the critical product development function.

Mr. Sushrut Kulkarni resigns as Global Head of IPDO and Senior Management Personnel.
The resignation is effective from May 8, 2026, providing a 3-month transition window.
The departure is intended for the executive to explore opportunities outside the company.
The Integrated Product Development Organization (IPDO) is a key division for the pharmaceutical firm's R&D.

💡 Investors should monitor for the appointment of a successor to lead the IPDO division. No immediate action is required as the long lead time minimizes operational disruption risks.

Dr. Reddy's to Participate in Nuvama Investor Conference on February 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Feb 2026, 03:11 PM

Dr. Reddy's Laboratories has announced its participation in an upcoming investor conference organized by Nuvama. The event is scheduled for February 9, 2026, in Mumbai and will be conducted as an in-person group meeting. The management will interact with institutional investors and groups throughout the day from 09:00 to 17:00 IST. This is a standard regulatory disclosure under SEBI Listing Obligations and Disclosure Requirements.

Meeting scheduled for February 9, 2026, in Mumbai.
Organized by Nuvama as an in-person group interaction.
Full-day engagement window from 09:00 to 17:00 IST.
Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should watch for any post-event presentations or transcripts that may provide updated guidance on the company's product pipeline or growth strategy.

Dr. Reddy's Q3FY26: Revenue Grows 4.4% to ₹8,727 Cr; Adjusted EBITDA Margin at 24.8%

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 27 Jan 2026, 10:48 PM

Dr. Reddy's reported a resilient Q3FY26 with revenue growth of 4.4% YoY to ₹8,727 crores, driven by double-digit growth in the base business excluding Lenalidomide. Reported PAT declined 14% YoY to ₹1,210 crores, impacted by lower Lenalidomide sales and a one-time provision for new Indian Labour Codes. Adjusted for this one-off, the EBITDA margin remained healthy at 24.8%. The company continues to strengthen its pipeline with the US BLA filing for Abatacept and DCGI approval for Semaglutide in India.

Consolidated revenue reached ₹8,727 crores, up 4.4% YoY, supported by branded markets and favorable forex.
Adjusted EBITDA margin stood at 24.8% after excluding a one-time labor code provision; reported margin was 23.5%.
Net cash surplus remains robust at ₹3,069 crores ($342 million) as of December 31, 2025.
Received DCGI marketing authorization for Semaglutide injection in India and filed US BLA for Abatacept biosimilar.
USFDA issued a Complete Response Letter (CRL) for Denosumab biosimilar due to partner Alvotech's facility observations.

💡 Investors should monitor the ramp-up of the base business to offset the declining Lenalidomide contribution and track regulatory progress on the Semaglutide and Abatacept pipelines. The stock remains a solid play on biosimilars and emerging market growth, supported by a strong net-cash balance sheet.

Dr. Reddy's Russian Subsidiary Faces INR 24.50 Million Tax Penalty

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 24 Jan 2026, 12:57 PM

Dr. Reddy's Laboratories' Russian subsidiary, Dr. Reddy’s Laboratories LLC, has received a tax audit decision from the Federal Tax Service of Russia. The authority has re-classified marketing services as taxable, resulting in a Value Added Tax (VAT) penalty of approximately INR 24.50 million (Rub 20.09 million). The company has stated that this penalty will not have a material impact on its consolidated financials or operations. Dr. Reddy's is currently evaluating a formal legal response to the authority's decision.

Penalty of Rub 20.09 million (approximately INR 24.50 million) imposed by Russian tax authorities.
The dispute involves the re-classification of marketing services as taxable for VAT purposes.
Management confirms no material impact on the company's overall financial or operational activities.
The tax audit decision was received on January 23, 2026, by the step-down wholly-owned subsidiary.

💡 No action is required as the penalty amount is insignificant relative to the company's annual revenue and market capitalization. This is a routine regulatory matter in international operations.

Dr. Reddy's Shares Audio Recording of Q3 FY2026 Earnings Call

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 21 Jan 2026, 10:56 PM

Dr. Reddy's Laboratories has released the audio recording of its earnings conference call for the quarter ended December 31, 2025. The call was conducted on January 21, 2026, following the announcement of the company's quarterly financial results. This disclosure is a routine regulatory requirement under SEBI (LODR) Regulations to ensure transparency for all stakeholders. Investors can access the full management commentary and Q&A session via the provided web link.

Earnings call for the quarter ended December 31, 2025, conducted on January 21, 2026
Audio recording link made available to the public via the company's website
Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Recording provides management insights into Q3 performance and future strategic outlook

💡 Investors should listen to the recording to understand management's perspective on margin trends and the product pipeline. No immediate action is required as this is a procedural filing.

View All DRREDDY Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Global Generics (GG) revenue grew 17% in FY2025 to INR 32,553.5 Cr, while PSAI (Pharmaceutical Services and Active Ingredients) margins were 27.1%. In Q2 FY2026, total revenue reached INR 8,805 Cr, a 10% YoY increase driven by broad-based growth and the acquired Consumer Healthcare business.

Geographic Revenue Split

Revenue is diversified across North America, India, Europe, and Emerging Markets. North America and Europe experienced price erosion in FY2025, while India and Emerging Markets were bolstered by the acquisition of the Stugeron brand (INR 100 Cr revenue size).

Profitability Margins

Gross Profit Margin stood at 54.7% in Q2 FY2026, down from 59.6% YoY due to price erosion and product mix changes. Profit After Tax (PAT) for Q2 FY2026 was INR 1,437 Cr (16.3% margin), representing a 14% YoY increase.

EBITDA Margin

EBITDA margin for Q2 FY2026 was 26.7% (INR 2,351 Cr), a 174 bps decline YoY. The underlying EBITDA margin, adjusting for a one-time VAT provision, was 27.5%. Management targets a return to 25% EBITDA margins by FY2027 despite the tapering of high-margin Lenalidomide sales.

Capital Expenditure

Annual capex is projected between INR 1,500 Cr and INR 2,000 Cr, primarily funded through internal accruals. Historical capex was utilized for plant expansions and strategic brand acquisitions like the Nestlé Consumer Healthcare business.

Credit Rating & Borrowing

Maintains an [ICRA]AA+ (Stable) rating. Financial profile is robust with an interest coverage ratio of 46.4x and a total debt/OPBDITA of 0.3x as of FY2024. Net cash surplus stood at INR 2,751 Cr ($310 million) in Q2 FY2026.

⚙️ Operational Drivers

Raw Materials

Key inputs include Active Pharmaceutical Ingredients (APIs) and intermediates. Cost of Revenues reached INR 3,991 Cr in Q2 FY2026, a 23% YoY increase, reflecting higher volumes and the impact of acquired businesses.

Import Sources

Sourced globally to support 32 manufacturing and R&D facilities across 83 markets served. Specific country splits are not disclosed, but operations are exposed to global supply chain dynamics.

Capacity Expansion

Operates 32 manufacturing and R&D plants globally. Expansion is focused on complex generics, biosimilars, and capacity for the newly acquired Consumer Healthcare portfolio.

Raw Material Costs

Cost of revenues as a % of revenue increased to 45.3% in Q2 FY2026 from 40.4% YoY. Procurement strategies focus on internal API production (PSAI segment) to mitigate external price volatility.

Manufacturing Efficiency

Annualized RoCE stood at ~22% in Q2 FY2026, down from 28% in FY2025, reflecting the deployment of cash into lower-yielding immediate-term acquisitions.

Logistics & Distribution

Distribution spans 83 markets. Selling, General & Administrative (SG&A) expenses were INR 2,644 Cr in Q2 FY2026 (30% of revenue), up 15% YoY due to investments in the consumer healthcare business.

📈 Strategic Growth

Expected Growth Rate

13-15%

Growth Strategy

Growth is driven by a 'triple-play' strategy: strengthening the core generics business, advancing a complex pipeline (Semaglutide, Abatacept), and aggressive M&A. Recent deals include the Nestlé Consumer Healthcare acquisition and the Stugeron brand for INR 420 Cr ($50M).

Products & Services

Generic medicines (Lenalidomide capsules), APIs, Biosimilars (Semaglutide), and Consumer Healthcare products (NRT business, Stugeron).

Brand Portfolio

Stugeron, Revlimid (generic version: Lenalidomide).

New Products/Services

Launched Lenacapavir for HIV prevention in LMICs. 85 filings are pending US FDA approval, including 17 expected First-to-File (FTF) statuses which provide 180-day exclusivity and higher revenue potential.

Market Expansion

Expanding presence in India and Emerging Markets through brand acquisitions. The Stugeron acquisition targets the India and Emerging Markets vertigo treatment segment.

Market Share & Ranking

Established as one of the leading Indian pharmaceutical companies with a presence in 83 markets.

Strategic Alliances

Partnered with Unitaid, Clinton Health Access Initiative, and Wits RHI for HIV tools. Collaborating with Nestlé for the Nutraceuticals subsidiary (49% ownership by Nestlé India).

🌍 External Factors

Industry Trends

The industry is shifting toward complex generics and biosimilars (e.g., Semaglutide) as simple generics face 10-15% annual price erosion. Dr. Reddy's is positioning itself through 17 potential FTF filings to capture high-value windows.

Competitive Landscape

Faces intense competition in the US generics market from other Indian and global players, leading to price erosion in select products.

Competitive Moat

Moat is built on R&D scale (7-9% of revenue) and a massive filing pipeline (85 pending approvals). This is sustainable due to a net cash position of INR 2,751 Cr, allowing for continuous reinvestment without debt pressure.

Macro Economic Sensitivity

Vulnerable to global healthcare policy changes and inflation in raw material costs which increased cost of revenues by 23% YoY in Q2 FY2026.

Consumer Behavior

Increasing demand for affordable HIV prevention (Lenacapavir) and weight management (Semaglutide) is shaping the R&D pipeline.

Geopolitical Risks

Operations in 83 markets expose the company to trade barriers and regulatory scrutiny from the US FDA, US SEC, and US DoJ.

⚖️ Regulatory & Governance

Industry Regulations

Subject to US FDA, US SEC, and US DoJ scrutiny. Successfully resolved past non-compliances, but ongoing maintenance of high manufacturing standards is critical to avoid import bans.

Environmental Compliance

Targeting carbon neutrality in Scope 1 and 2 by 2030. Achieved water positivity and 42% renewable power usage as of FY2023.

Taxation Policy Impact

Effective tax rate was 22.2% in Q2 FY2026 (INR 408 Cr). FY2025 tax expense was INR 1,953.9 Cr (25.4% of PBT).

Legal Contingencies

Faces ongoing investigations and product litigations. An impairment charge of INR 66 Cr was taken in Q2 FY2026, including INR 54 Cr for the Middleburgh facility following the discontinuation of the Conjugated Estrogen pipeline product.

⚠️ Risk Analysis

Key Uncertainties

Adverse outcomes from ongoing lawsuits or US FDA inspections could significantly impact liquidity and market access. Tapering of Lenalidomide revenue poses a margin risk (potential drop below 25% EBITDA).